|

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts W/Chronic Myeloid Leukemia

RECRUITINGSponsored by University of California, Irvine
Actively Recruiting
SponsorUniversity of California, Irvine
Started2024-01-25
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06229860

Summary

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* 18 years of age or older
* Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)
* Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib
* A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or
* A member of a patient support group organized by the CML Buster Foundation
* Do not meet any of the criteria listed under "Exclusion Requirements"

Exclusion Criteria:

* Unable to read and speak English
* Impaired decisional capacity to consent

Conditions3

CancerChronic Myeloid LeukemiaChronic Phase Chronic Myelogenous Leukemia

Locations1 site

Chao Family Comprehensive Cancer Center University of California, Irvine
Orange, California, 92868
Mahtab Jafari, Pharm.D877-827-8839ucstudy@uci.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.